Critically short telomeres and toxicity of chemotherapy in early breast cancer.

Simple item page
dc.contributor.authorQuintela-Fandino, Miguel
dc.contributor.authorSoberon, Nora
dc.contributor.authorLluch, Ana
dc.contributor.authorManso, Luis
dc.contributor.authorCalvo, Isabel
dc.contributor.authorCortes, Javier
dc.contributor.authorMoreno-Antón, Fernando
dc.contributor.authorGil-Gil, Miguel
dc.contributor.authorMartinez-Jánez, Noelia
dc.contributor.authorGonzalez-Martin, Antonio
dc.contributor.authorAdrover, Encarna
dc.contributor.authorde Andres, Raquel
dc.contributor.authorViñas, Gemma
dc.contributor.authorLlombart-Cussac, Antonio
dc.contributor.authorAlba, Emilio
dc.contributor.authorMouron, Silvana
dc.contributor.authorGuerra, Juan
dc.contributor.authorBermejo, Begoña
dc.contributor.authorZamora, Esther
dc.contributor.authorGarcía-Saenz, Jose Angel
dc.contributor.authorSimon, Sonia Pernas
dc.contributor.authorCarrasco, Eva
dc.contributor.authorEscudero, María José
dc.contributor.authorCampo, Ruth
dc.contributor.authorColomer, Ramón
dc.contributor.authorBlasco, Maria A
dc.date.accessioned2025-01-07T13:01:05Z
dc.date.available2025-01-07T13:01:05Z
dc.date.issued2017
dc.description.abstractCumulative toxicity from weekly paclitaxel (myalgia, peripheral neuropathy, fatigue) compromises long-term administration. Preclinical data suggest that the burden of critically short telomeres ( 21.9% CSTs) had 2-fold higher number of neuropathy (P = 0.04) or fatigue (P = 0.019) episodes and >3-fold higher number of myalgia episodes (P = 0.005). The average telomere length was unrelated to the incidence of side effects.The percentage of CSTs, but not the average telomere size, is associated with weekly paclitaxel-derived toxicity.
dc.identifier.doi10.18632/oncotarget.15592
dc.identifier.essn1949-2553
dc.identifier.pmcPMC5400599
dc.identifier.pmid28423524
dc.identifier.pubmedURLhttps://pmc.ncbi.nlm.nih.gov/articles/PMC5400599/pdf
dc.identifier.unpaywallURLhttp://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=15592&path%5B%5D=49804
dc.identifier.urihttps://hdl.handle.net/10668/25129
dc.issue.number13
dc.journal.titleOncotarget
dc.journal.titleabbreviationOncotarget
dc.language.isoen
dc.organizationSAS - Hospital Universitario de Jerez de la Frontera
dc.organizationSAS - Hospital Universitario Virgen Macarena
dc.page.number21472-21482
dc.pubmedtypeJournal Article
dc.pubmedtypeRandomized Controlled Trial
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectbreast cancer
dc.subjectcritically short telomeres
dc.subjecttelomere length
dc.subjecttoxicity
dc.subjectweekly paclitaxel
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntineoplastic Agents
dc.subject.meshBreast Neoplasms
dc.subject.meshChemotherapy, Adjuvant
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshIn Situ Hybridization, Fluorescence
dc.subject.meshIndoles
dc.subject.meshMiddle Aged
dc.subject.meshNeoadjuvant Therapy
dc.subject.meshPaclitaxel
dc.subject.meshTelomere
dc.subject.meshTelomere Shortening
dc.titleCritically short telomeres and toxicity of chemotherapy in early breast cancer.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number8

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PMC5400599.pdf
Size:
8.44 MB
Format:
Adobe Portable Document Format
Download

Collections

SAS - Hospital Universitario de Jerez de la Frontera
SAS - Hospital Universitario Virgen Macarena

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía